➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Moodys
Mallinckrodt
Colorcon
McKinsey

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Sulfatinib


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Sulfatinib?

Sulfatinib is an investigational drug.

There have been 11 clinical trials for Sulfatinib. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2015.

The most common disease conditions in clinical trials are Neuroendocrine Tumors, Carcinoid Tumor, and Biliary Tract Neoplasms. The leading clinical trial sponsors are Hutchison Medipharma Limited, Peking University, and [disabled in preview].

There are two US patents protecting this investigational drug and twenty international patents.

Recent Clinical Trials for Sulfatinib
TitleSponsorPhase
A Phase IIb/III Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma PatientsHutchison Medipharma LimitedPhase 2/Phase 3
Trial of Sulfatinib Combined With JS001 in the Treatment of Advanced Solid TumorsPeking UniversityPhase 1
To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different ManufacturersHutchison Medipharma LimitedPhase 1

See all Sulfatinib clinical trials

Clinical Trial Summary for Sulfatinib

Top disease conditions for Sulfatinib
Top clinical trial sponsors for Sulfatinib

See all Sulfatinib clinical trials

US Patents for Sulfatinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sulfatinib   Start Trial Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use Hutchison MediPharma Limited (Shanghai, CN)   Start Trial
Sulfatinib   Start Trial Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use Hutchison Medipharma Limited (Shanghai, CN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sulfatinib

Drugname Country Document Number Estimated Expiration Related US Patent
Sulfatinib Australia 2010321366 2029-11-23   Start Trial
Sulfatinib Brazil 112012012138 2029-11-23   Start Trial
Sulfatinib Canada 2781066 2029-11-23   Start Trial
Sulfatinib China 102070618 2029-11-23   Start Trial
Sulfatinib China 102648194 2029-11-23   Start Trial
Sulfatinib Denmark 2504331 2029-11-23   Start Trial
Sulfatinib European Patent Office 2504331 2029-11-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Baxter
Express Scripts
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.